ABSTRACT
Dietary food components have the ability to affect immune function; following absorption, specifically orally ingested dietary food containing lectins can systemically modulate the immune cells and affect the response to self- and co-administered food antigens. The mannose-binding lectins from garlic (Allium sativum agglutinins; ASAs) were identified as immunodulatory proteins in vitro. The objective of the present study was to assess the immunogenicity and adjuvanticity of garlic agglutinins and to evaluate whether they have adjuvant properties in vivo for a weak antigen ovalbumin (OVA). Garlic lectins (ASA I and ASA II) were administered by intranasal (50 days duration) and intradermal (14 days duration) routes, and the anti-lectin and anti-OVA immune (IgG) responses in the control and test groups of the BALB/c mice were assessed for humoral immunogenicity. Lectins, co-administered with OVA, were examined for lectin-induced anti-OVA IgG response to assess their adjuvant properties. The splenic and thymic indices were evaluated as a measure of immunomodulatory functions. Intradermal administration of ASA I and ASA II had showed a four-fold and two-fold increase in anti-lectin IgG response, respectively, vs. the control on day 14. In the intranasal route, the increases were 3-fold and 2.4-fold for ASA I and ASA II, respectively, on day 50. No decrease in the body weights of animals was noticed; the increases in the spleen and thymus weights, as well as their indices, were significant in the lectin groups. In the adjuvanticity study by intranasal administration, ASA I co-administered with ovalbumin (OVA) induced a remarkable increase in anti-OVA IgG response (~six-fold; p < 0.001) compared to the control, and ASA II induced a four-fold increase vs. the control on day 50. The results indicated that ASA was a potent immunogen which induced mucosal immunogenicity to the antigens that were administered intranasally in BALB/c mice. The observations made of the in vivo study indicate that ASA I has the potential use as an oral and mucosal adjuvant to deliver candidate weak antigens. Further clinical studies in humans are required to confirm its applicability.
Subject(s)
Adjuvants, Immunologic , Garlic/chemistry , Immunity, Humoral , Lectins/immunology , Administration, Intranasal , Administration, Mucosal , Animals , Biomarkers , Enzyme-Linked Immunosorbent Assay , Immunization/methods , Immunoglobulin G/immunology , Immunomodulation , Lectins/administration & dosage , Lectins/isolation & purification , Mice , Mice, Inbred BALB C , Organ Specificity/immunology , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Plant Extracts/pharmacologyABSTRACT
OBJECTIVE: Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer. METHODS: We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of <15 on the Gloria Bachman Vaginal Health Index (VHI) comprised of five items including: vaginal pH, elasticity, fluid volume (secretions), epithelial integrity, and moisture.We administered intramucosal injections of A-PRP combined with HA (Regenkit) and performed clinical evaluations at 0, 1, 3, and 6 months. Primary endpoint: evaluation of vulvovaginal mucosa changes using the VHI; secondary endpoint: evaluation of dyspareunia and sexual dysfunction based on the Female Sexual Distress (FSD) score. RESULTS: All participants (20 women) showed improvement in the clinical symptoms of vaginal dryness and dyspareunia. The VHI score showed a significant increase at 6 months, going from a total baseline score (pretreatment) of 10.7â±â2.12 to 20.75â±â4.8 (Pâ<â0.0001) at 6 months. Improvement in hydration and vaginal epithelial integrity was reported. A VHI score of > 15 showed a successful treatment outcome. The FSD score decreased significantly during the study, from a baseline score of 36.35â±â2.53 pretreatment to 30.15â±â2.47 6 months after treatment, representing improvement of 17% (Pâ<â0.0001, respectively). No adverse events were reported. CONCLUSIONS: The injection of A-PRP-HA appeared to be a promising method to improve the trophicity and hydration of vaginal mucosa for the treatment of VVA in postmenopausal breast cancer survivors with contraindications to hormone therapy.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Breast Neoplasms , Cancer Survivors , Hyaluronic Acid/therapeutic use , Platelet-Rich Plasma , Postmenopause/physiology , Vagina/pathology , Vulva/pathology , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/adverse effects , Administration, Mucosal , Aged , Analysis of Variance , Atrophy/drug therapy , Complementary Therapies/methods , Female , Follow-Up Studies , France , Hospitals, University , Humans , Hyaluronic Acid/administration & dosage , Hyaluronic Acid/adverse effects , Middle Aged , Patient Satisfaction , Pilot Projects , Prospective Studies , Regenerative Medicine/methods , Sexual Dysfunction, Physiological/drug therapy , Treatment OutcomeABSTRACT
AIM: An anthocyanin complex (AC), combined Zea mays and Clitoria ternatea extracts, was evaluated for topical oral wound healing in rats and a clinical trial in orthodontic patients. METHODS/RESULTS: AC enhanced anthocyanin permeation in vitro. In rats, 10% w/w of AC in a mucoadhesive gel (AG) reduced erythema and sizes of oral wounds after topical applications at higher extent than its placebo gel. Acute orthodontic wounds in 68 volunteers were randomly assigned to topically receive either AG or placebo gel and double-blind assessed. Wound size reduction and wound closure enhancement were obvious in AG-treated group on day 3 (p < 0.05). CONCLUSION: At 10% w/w, AC promoted wound closure and possessed a potential in healing stimulation of acute oral wounds.
Subject(s)
Anthocyanins/pharmacology , Mouth Mucosa/injuries , Plant Extracts/pharmacology , Stomatitis, Denture/drug therapy , Wound Healing/drug effects , Administration, Mucosal , Adult , Animals , Anthocyanins/therapeutic use , Clitoria/chemistry , Double-Blind Method , Drug Evaluation, Preclinical , Female , Humans , Male , Mouth Mucosa/metabolism , Orthodontic Brackets/adverse effects , Plant Extracts/therapeutic use , Rats , Rats, Wistar , Stomatitis, Denture/etiology , Treatment Outcome , Young Adult , Zea mays/chemistryABSTRACT
We investigated if a carbohydrate (CHO) mouth rinse may attenuate global fatigue and improve 4-km cycling time trial (TT4km) performance. After a preliminary session, cyclists (n = 9) performed a TT4km after a CHO or placebo (PLA) mouth rinse. Mean power output, time, and ratings of perceived exertion (RPE) were recorded throughout the TT4km. Twitch interpolation responses (%VA; voluntary activation and ∆Tw; delta peak twitch torque) were compared pre and post TT4km with traditional statistics and effect size (ES) analysis. Time-to-complete the 4 km and mean power output were comparable between CHO (386.4 ± 28.0 s) and PLA (385.4 ± 22.4 s). A lower central (p = 0.054) and peripheral (p = 0.02) fatigue in CHO than in PLA were suggested by an extremely-large ES in %VA (manipulation main effect: p = 0.052, d = 1.18; manipulation-by-time interaction effect: p = 0.08, d = 1.00) and an extremely, very-large ES in ∆Tw (manipulation main effect: p = 0.07, d = 0.97; time-by-manipulation interaction effect: p = 0.09, d = 0.89). The RPE increased slower in CHO than in PLA (p = 0.051; d = 0.7). The apparent reduction in global fatigue (central and peripheral) and RPESLOPE with only one CHO mouth rinse were not translated into improved TT4km performance. Further tests may be required to verify if these likely differences in global fatigue might represent an edge in the short-lasting cycling time trial performance.
Subject(s)
Athletic Performance , Bicycling , Dietary Carbohydrates/administration & dosage , Fatigue/prevention & control , Mouthwashes/administration & dosage , Performance-Enhancing Substances/administration & dosage , Administration, Mucosal , Adult , Brazil , Dietary Carbohydrates/metabolism , Dietary Carbohydrates/therapeutic use , Dietary Supplements , Double-Blind Method , Fatigue/etiology , Fatigue/metabolism , Humans , Male , Mouthwashes/metabolism , Mouthwashes/therapeutic use , Muscle Fatigue , Oral Mucosal Absorption , Oxygen Consumption , Performance-Enhancing Substances/metabolism , Performance-Enhancing Substances/therapeutic use , Physical Exertion , Recreation , Sports Nutritional Physiological Phenomena , Time FactorsABSTRACT
BACKGROUND AND OBJECTIVE: The aim of this study was to test the hypothesis that tincture of benzoin (TOB) facilitates immediate transmucosal nicotine absorption while simultaneously promoting a safe and sustained delivery of the nicotine. METHODS: In combination with TOB, nicotine toxicity and diffusion across human mucosal cells were measured using a 3-D human mucosal tissue model. RESULTS: Nicotine was delivered 2.1 times more quickly in combination with TOB than in combination with saline (p < 0.05). Despite the increased diffusion, nicotine in combination with TOB significantly increased mucosal cell survival (p < 0.05) by reducing the release of mitochondrial cytochrome c into the cytoplasm when compared with nicotine without TOB. The average percentage distribution of cytochrome c in the cytosolic fraction over time of nicotine + 79% ethyl alcohol (ETOH) versus nicotine plus TOB (79% ETOH) was significantly different over 120 min (60.0 ± 29.9% cytosol, 16.1 ± 9.4% cytosol, p = 0.03). Related to the reduction of cytochrome c release into the cytoplasm, TOB suppressed caspase-3 and -9 activity, thereby preventing intrinsic apoptosis and providing cytoprotection of the mucosal cells (ETOH + nicotine vs ETOH + nicotine + TOB: p = 0.008 for caspase 3, p < 0.001 for caspase 9). CONCLUSION: Two hours of TOB (17-24% benzoin, 79% ETOH) plus nicotine promotes diffusion of nicotine across human mucosal cells and simultaneously prevents human mucosal cell toxicity by inhibiting cytochrome c release into the cytosol, thereby preventing caspase 3 and 9 activity and subsequent intrinsic apoptosis.
Subject(s)
Apoptosis/drug effects , Mouth Mucosa/metabolism , Nicotine Chewing Gum , Nicotine/administration & dosage , Plant Extracts/administration & dosage , Administration, Mucosal , Caspase 3/metabolism , Caspase 9/metabolism , Cells, Cultured , Cytochromes c/metabolism , Diffusion , Humans , Models, Biological , Mouth Mucosa/drug effects , Nicotine/pharmacokinetics , Nicotine/toxicity , Oral Mucosal Absorption , Plant Extracts/pharmacokinetics , Plant Extracts/toxicity , Styrax/toxicity , Tissue Survival/drug effectsABSTRACT
PURPOSE: This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment. METHODS: A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each administered a single dose of oral transmucosal fentanyl citrate (OTFC) or a single dose of OTFC with mEHT. mEHT was performed on the abdomen for 1 hour. Blood samples were collected for 24 hours after dosing. The temperature of the abdominal skin surface was assessed before dosing and at 10, 20, and 60 minutes after dosing. FINDINGS: Geometric mean ratios (ratio of fentanyl with mEHT to fentanyl alone) for the Cmax and AUC0-last were 1.20 (90% CI, 1.09-1.32) and 1.15 (90% CI, 0.99-1.33), respectively. The mean temperature of the abdominal skin surface increased by approximately 4°C. IMPLICATIONS: There was an increase in the overall exposure to the drug without implications of any clinical significance. OTFC can be administered without limitations in combination with mEHT, and it is not necessary to modify the dosing regimen. cris.nih.go,kr Identifier: KCT0001286.
Subject(s)
Analgesics, Opioid/pharmacokinetics , Fentanyl/pharmacokinetics , Hyperthermia, Induced , Administration, Mucosal , Administration, Oral , Adult , Cross-Over Studies , Electricity , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
This study introduces a new approach for enhancing immunity toward mucosal vaccines. HEV71 killed vaccine that is formulated with nanosize calcium phosphate adjuvant and encapsulated onto chitosan and alginate delivery carriers was examined for eliciting antibody responses in serum and saliva collected at weeks 0, 1, 3, 5, 7 and 9 for viral-specific IgA & IgG levels and viral neutralizing antibody titers. The antibody responses induced in rabbits by the different formulations delivered by a single (buccal) route were compared to those of dual immunization (intradermal / mucosal) and un-immunized control. Chitosan-loaded vaccine adjuvant induced elevated IgA antibody, while Alginate-adjuvant irreversible bonding sequestered the vaccine and markedly reduced immunogenicity. The induced mucosal and parenteral antibody profiles appeared in an inverse manner of enhanced mucosal IgA antibody accompanied by lower systemic IgG following a single oral immunization route. The combined intradermal and oral dual-immunized group developed an elevated salivary IgA, systemic IgG, and virus neutralizing response. A reduced salivary neutralizing antibody titer was observed and attributed to the continual secretion exchanges in saliva. Designing a successful mucosal delivery formulation needs to take into account the vaccine delivery site, dosage, adjuvant and carrier particle size, charge, and the reversibility of component interactions. The dual immunization seems superior and is a important approach for modulating the antibody response and boosting mucosal protection against HEV71 and similar pathogens based on their transmission mode, tissue tropism and shedding sites. Finally, the study has highlighted the significant role of dual immunization for simultaneous inducing and modulating the systemic and mucosal immune responses to EV71.
Subject(s)
Adjuvants, Immunologic/administration & dosage , Antibodies, Neutralizing/analysis , Antibodies, Viral/analysis , Calcium Phosphates/administration & dosage , Chitosan/administration & dosage , Enterovirus A, Human/immunology , Viral Vaccines/immunology , Administration, Mucosal , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Drug Carriers/administration & dosage , Immunity, Mucosal , Immunoglobulin A/analysis , Immunoglobulin G/blood , Injections, Intradermal , Rabbits , Saliva/chemistry , Serum/chemistry , Viral Vaccines/administration & dosageABSTRACT
Conventional drugs have only a limited impact on spasticity associated with multiple sclerosis and are rarely satisfactory. A solution for oral transmucosal delivery (spray) containing a mixture of cannabis extracts (2.7 mg of delta-9-tetrahydrocannabinol + 2.5 mg of cannabidiol per spray) has been granted marketing authorisation in France for patients who are inadequately relieved by standard treatments. Three double-blind, placebo-controlled trials in a total of about 300 patients tested this combination, in addition to ongoing treatment, for periods of 6 to 14 weeks. Individually, none of these trials showed any tangible anti-spastic efficacy, but two combined analyses showed "response rates" of about 35% with the mixture versus about 25% with placebo. In a trial with 572 patients, the 241 patients who "responded" after 4 weeks of treatment were randomised to either continue using the cannabis extract or receive placebo. Twelve weeks later, 75% of patients using the extract were still "responders", versus 51% of patients switched to placebo. The principal adverse effects of the cannabis extracts consist of neuropsychiatric disorders that resolve on treatment withdrawal. The potential for abuse increases with the dose and is tangible from 16 sprays per day. Pharmacokinetic interactions due to P-glycoprotein inhibition are likely. Treatment during pregnancy may lead to neonatal withdrawal symptoms. In practice, about 10% of patients in whom standard anti-spastic medications are unsatisfactory benefit from a specific effect of the cannabis extracts contained in this oral spray.
Subject(s)
Dronabinol/therapeutic use , Multiple Sclerosis/drug therapy , Neuromuscular Agents/therapeutic use , Administration, Mucosal , Aerosols , Cannabidiol/therapeutic use , Dronabinol/administration & dosage , Dronabinol/adverse effects , Dronabinol/pharmacokinetics , Drug Administration Schedule , Drug Combinations , Drug Interactions , Drug Packaging , Drug Storage , Evidence-Based Medicine , Humans , Multiple Sclerosis/diagnosis , Neuromuscular Agents/administration & dosage , Neuromuscular Agents/adverse effects , Neuromuscular Agents/pharmacokinetics , Treatment OutcomeABSTRACT
BACKGROUND: Therapeutic gene transfer is currently being evaluated as a potential therapy for inflammatory bowel disease. This study investigates the safety and therapeutic benefit of a locally administered lentiviral vector encoding murine interleukin-10 in altering the onset and relapse of dextran sodium sulfate induced murine colitis. METHODS: Lentiviral vectors encoding the reporter genes firefly-luciferase and murine interleukin-10 were administered by intrarectal instillation, either once or twice following an ethanol enema to facilitate mucosal uptake, on Days 3 and 20 in Balb/c mice with acute and relapsing colitis induced with dextran sulfate sodium (DSS). DSS colitis was characterized using clinical disease activity, macroscopic, and microscopic scores. Bioluminescence optical imaging analysis was employed to examine mucosal lentiviral vector uptake and transgene expression. Levels of tumor necrosis factor-α and interleukin-6 in homogenates of rectal tissue were measured by ELISA. Biodistribution of the lentiviral vector to other organs was evaluated by real time quantitative PCR. RESULTS: Mucosal delivery of lentiviral vector resulted in significant transduction of colorectal mucosa, as shown by bioluminescence imaging analysis. Lentiviral vector-mediated local expression of interleukin-10 resulted in significantly increased levels of this cytokine, as well as reduced levels of tumor necrosis factor-α and interleukin-6, and significantly reduced the clinical disease activity, macroscopic, and microscopic scores of DSS colitis. Systemic biodistribution of locally instilled lentiviral vector to other organs was not detected. CONCLUSIONS: Topically-delivered lentiviral vectors encoding interleukin-10 safely penetrated local mucosal tissue and had therapeutic benefit in this DSS model of murine colitis.
Subject(s)
Colitis/therapy , Genetic Therapy/methods , Genetic Vectors , Interleukin-10/genetics , Lentivirus , Administration, Mucosal , Administration, Rectal , Animals , Colitis/chemically induced , Colitis/prevention & control , Dextran Sulfate/toxicity , Disease Models, Animal , Gene Transfer Techniques , Mice , Mice, Inbred BALB C , RecurrenceABSTRACT
BACKGROUND: Budesonide is a potent corticosteroid commonly prescribed for management of inflammation in chronic rhinosinusitis (CRS). The standard for prescribing budesonide is via impregnated nasal saline irrigation (INSI), although recently the mucosal atomization device (MAD) has emerged as a theoretically superior method of distributing medication into the sinuses. The MAD atomizes medication into small droplets and this is thought to enhance absorption and improve bioavailability. However, no studies have shown whether enhanced absorption and improved bioavailability of budesonide via MAD causes adrenal suppression. The objective of this study is to determine whether budesonide via MAD affects the hypothalamic-pituitary-adrenal (HPA) axis. METHODS: Twenty CRS patients were recruited from a tertiary rhinology clinic and randomized to take budesonide (1 mg) via MAD or via INSI twice a day for 60 days. The adrenocorticotropic hormone (ACTH) stimulation test and 22-item Sinonasal Outcomes Test (SNOT-22) questionnaire were administered on days 1, 30, and 60 of the study. Plasma budesonide and cortisol levels were simultaneously quantified using a high-performance liquid chromatography-tandem mass spectrometry technique. RESULTS: There was no indication of adrenal suppression in either group (n = 20) based on ACTH stimulation test results nor was there significant plasma budesonide levels detected in either group. Quality of life, as indicated by SNOT-22, did not differ between groups at 60 days (p = 0.404; 95% confidence interval [CI], -37.2 to 15.9), but SNOT-22 scores for patients using MAD did show statistically significant improvement at 60 days compared to baseline (p = 0.02). CONCLUSION: The MAD is likely a safe and effective method of delivering budesonide to the sinuses in the short term.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Budesonide/administration & dosage , Rhinitis/drug therapy , Sinusitis/drug therapy , Administration, Mucosal , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/pharmacokinetics , Budesonide/adverse effects , Budesonide/pharmacokinetics , Canada , Chronic Disease , Female , Humans , Hydrocortisone/metabolism , Hypothalamo-Hypophyseal System/drug effects , Male , Nasal Polyps/complications , Nebulizers and Vaporizers/statistics & numerical data , Pituitary-Adrenal System/drug effects , Prospective Studies , Quality of Life , Rhinitis/complications , Sinusitis/complications , Time Factors , Treatment OutcomeABSTRACT
INTRODUCTION: We investigated the effects of topical anesthesia of the oral mucosa by using an adhesive patch instilled with 2% lidocaine hydrochloride solution. METHODS: The subjects were 20 healthy adult volunteers who gave written informed consent. Each patient was treated in a randomized crossover fashion with a hemostatic adhesive patch instilled with one of the following agents: 2% lidocaine hydrochloride with 12.5 µg/mL epinephrine, 2% lidocaine hydrochloride, 20% ethyl aminobenzoate, or physiological saline solution. A cotton ball containing 20% ethyl aminobenzoate was also tested. The adhesive patch or cotton ball was placed on the gingivobuccal fold of the maxillary right canine for 2 or 5 minutes. Then, a 33-gauge or 30-gauge needle was inserted to a depth of 2 mm. Insertion pain was evaluated with a visual analog scale (VAS) and a 4-level verbal rating scale immediately after needle removal. Efficacy of analgesia was calculated from the verbal rating scale. RESULTS: The VAS was lower and the efficacy of analgesia was higher on 33-gauge needle insertion than on 30-gauge needle insertion in all treatments. The VAS was also significantly lower and the efficacy of analgesia was higher in the lidocaine groups than in the other groups. Adding epinephrine did not enhance the anesthetic effect of lidocaine hydrochloride. CONCLUSIONS: Topical mucosal anesthesia with an adhesive patch containing 2% lidocaine hydrochloride solution is simple and may be more effective than conventional methods.
Subject(s)
Anesthesia, Dental/instrumentation , Anesthesia, Local/instrumentation , Anesthetics, Local/administration & dosage , Lidocaine/administration & dosage , Administration, Mucosal , Adult , Analgesia/methods , Benzocaine/administration & dosage , Cross-Over Studies , Cuspid/drug effects , Double-Blind Method , Epinephrine/administration & dosage , Female , Gingiva/drug effects , Humans , Male , Mouth Mucosa/drug effects , Needles , Pain Measurement/methods , Vasoconstrictor Agents/administration & dosageABSTRACT
Evidence available from nutritional epidemiology has indicated an inverse association between regular consumption of fruits and vegetables and the risk of developing certain types of cancer. In turn, preclinical studies have attributed the health-promoting effects of plant foods to some groups of phytochemicals, by virtue of their many biological activities. In this survey, we briefly examine the chemopreventive potential of flavonoids and flavonoid-rich foods in human oral carcinogenesis. Despite the paucity of data from clinical trials and epidemiological studies, in comparison to in vitro/in vivo investigations, a high level of evidence has been reported for epigallocatechin gallate (EGCG) and anthocyanins. These flavonoids, abundant in green tea and black raspberries, respectively, represent promising chemopreventive agents in human oral cancer.
Subject(s)
Anticarcinogenic Agents/therapeutic use , Flavonoids/therapeutic use , Mouth Neoplasms/prevention & control , Administration, Mucosal , Anticarcinogenic Agents/pharmacokinetics , Catechin/analogs & derivatives , Catechin/therapeutic use , Chemoprevention , Drug Delivery Systems , Flavonoids/pharmacokinetics , Fruit/chemistry , Humans , Mouth Neoplasms/drug therapy , Nanoparticles/chemistry , Polyphenols/therapeutic use , Randomized Controlled Trials as Topic , Tea/chemistryABSTRACT
WHAT IS KNOWN AND OBJECTIVE: Stiff-person syndrome (SPS) is an uncommon and disabling disorder characterized by progressive rigidity and episodic painful spasms involving axial and limb musculature. SPS treatment is mostly based on benzodiazepines, baclofen, immunosuppressants and intravenous immunoglobulin. Cannabis derivatives [tetrahydrocannabinol (THC) and cannabidiol (CBD)] are available as an oromucosal spray (Sativex(®)), indicated as add-on treatment, for symptom improvement in patients with moderate to severe spasticity because of multiple sclerosis (MS). Our objective is to report a case of seronegative SPS successfully treated with THC-CBD oromucosal spray. CASE SUMMARY: We report a case of a 40-year-old man presenting with progressive muscle stiffness and intermittent spasms for 6-years. The diagnosis of stiff-person syndrome was based on the clinical features and neuroelectrophysiologic findings of continuous motor unit activity. Glutamic acid decarboxylase autoantibodies was absent in our patient, in both serum and cerebrospinal fluid (CSF). Cannabis derivatives oromucosal spray was introduced after a series of unsatisfactory traditional medical treatments. After 14 months treated with THC-CBD oromucosal spray, improvement was verified in the eight dimensions of the scale of SF-36 quality of life questionnaire. WHAT IS NEW AND CONCLUSION: Clinical experience with cannabis derivatives in patients with multiple sclerosis is accumulating steadily, but there is no current literature about its efficacy for SPS. Because MS and SPS share some neurological symptoms such as spasticity and rigidity, it is thought that THC-CBC can be an option for SPS patient. Our case report suggests that THC-CBD oromucosal spray is an alternative treatment for patients with refractory SPS, and further validation is appropriate.
Subject(s)
Plant Extracts/therapeutic use , Quality of Life , Stiff-Person Syndrome/drug therapy , Administration, Mucosal , Adult , Cannabidiol , Dronabinol , Drug Combinations , Humans , Male , Plant Extracts/administration & dosage , Stiff-Person Syndrome/physiopathology , Surveys and Questionnaires , Treatment OutcomeABSTRACT
BACKGROUND: Spasticity is common in patients with multiple sclerosis (MS) and is a major contributor to disability. Sativex®, an oromucosal spray containing cannabis-based medicinal products, has been found to be effective in reducing spasticity symptoms. OBJECTIVE: Our objective was to estimate the cost effectiveness of Sativex® plus oral anti-spasticity medicines compared with the current standard treatment for moderate or severe spasticity in MS in the UK. METHODS: A Markov model was used to assess the costs and benefits of Sativex® plus oral anti-spasticity medicines or current standard treatment based on their effects on the quality of life of patients. The main outcome was the incremental cost-effectiveness ratio (ICER) in terms of costs per additional QALY gained over 5 years of treatment. One-way, multi-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the findings. RESULTS: In the base case, Sativex® plus oral anti-spasticity medicines resulted in incremental costs of £7600 and a QALY gain of 0.15 per person over 5 years (ICER = £49 300 per QALY).[year 2009 data for costs]. Findings were sensitive to the costs of Sativex® (price and dose) and differences in utilities between responders and non-responders. CONCLUSIONS: Using a willingness-to-pay threshold of £30 000 per QALY, Sativex® appears unlikely to be considered cost effective by UK funders of healthcare for spasticity in MS. This is unfortunate, since it appears that Sativex® use is likely to benefit some patients in the management of this common consequence of MS.
Subject(s)
Multiple Sclerosis/drug therapy , Muscle Relaxants, Central/therapeutic use , Muscle Spasticity/drug therapy , Plant Extracts/therapeutic use , Administration, Mucosal , Administration, Oral , Cannabidiol , Cost-Benefit Analysis , Dronabinol , Drug Combinations , Drug Therapy, Combination , Female , Humans , Male , Markov Chains , Middle Aged , Multiple Sclerosis/physiopathology , Muscle Relaxants, Central/administration & dosage , Muscle Relaxants, Central/economics , Muscle Spasticity/economics , Muscle Spasticity/etiology , Plant Extracts/administration & dosage , Plant Extracts/economics , Quality-Adjusted Life Years , Severity of Illness Index , United KingdomABSTRACT
Gastric variceal bleeding is a common problem in patients with cirrhosis and despite early endoscopic and/or pharmacological therapy, variceal bleeding cannot be controlled or recurs early in about 10 to 20% of patients with considerable morbidity and mortality rates. For this reason, effective control of active bleeding varices is of great importance for the prevention of late complications. Although endoscopic band ligation and sclerotherapy are the choice of endoscopic treatment modalities with various grades of success, limited data is available for the use of Ankaferd Blood Stopper (ABS) for the controlling of variceal bleeding due to gastric varices. We herein present a unique case of gastric variceal bleeding despite cyanoacrilate injection, which was successfully controlled with topical ABS application.
Subject(s)
Cyanoacrylates/administration & dosage , Esophageal and Gastric Varices/drug therapy , Gastrointestinal Hemorrhage/drug therapy , Gastroscopy , Hemostatics/therapeutic use , Plant Extracts/therapeutic use , Administration, Mucosal , Esophageal and Gastric Varices/complications , Female , Gastrointestinal Hemorrhage/etiology , Hemostatics/administration & dosage , Humans , Injections, Intralesional , Liver Cirrhosis , Middle Aged , Plant Extracts/administration & dosage , Treatment OutcomeABSTRACT
Phosphorylcholine (PC) is an immunodominant epitope in some pathogens including Streptococcus pneumoniae and it is well-known that PC-specific antibodies (Abs) play a key role in the induction of protective immunity against pneumococcal infection. In this study, we examined whether nasal administration of DNA plasmid encoding Flt3 ligand gene (pFL) as a mucosal adjuvant plus PC-conjugated keyhole limpet hemocyanin (PC-KLH), would elicit PC-specific immune responses, and characterized mucosal immune responses to PC induced by this nasal vaccination. Nasal immunization with pFL plus PC-KLH enhanced induction of PC-specific IgA and IgM Abs in airway secretions when compared with mice given PC-KLH with or without empty plasmid gene (pORF) as controls; in addition to the mucosal immune responses, PC-specific immune responses in serum were also induced. Furthermore, the mucosal and serum IgA and IgM Abs in mice given pFL plus PC-KLH nasally, exhibited high-specificity for the PC molecule. Of interest, the PC-specific Abs bound dose-dependently to anti-T15 idiotype (AB1-2). Thus, the inhibition of S. pneumoniae colonization on the nasal cavity and lungs after nasal challenge with the live organism was significantly elicited in mice immunized with pFL plus PC-KLH compared to that of mice immunized with antigen with pORF. Taken together, these findings show that nasal administration of pFL with PC-KLH elicited T15-like anti-PC IgA and IgM Abs in the respiratory tracts, and further attenuated S. pneumoniae colonization on the respiratory tracts. Nasal administration of Flt3 ligand cDNA with PC may contribute to the development of nasal vaccination for prevention of S. pneumoniae infection.
Subject(s)
Bacterial Vaccines/immunology , Membrane Proteins/immunology , Phosphorylcholine/immunology , Streptococcus pneumoniae/immunology , Administration, Intranasal , Administration, Mucosal , Animals , Antibodies, Bacterial/immunology , Bacterial Vaccines/administration & dosage , DNA, Complementary/immunology , Hemocyanins/administration & dosage , Hemocyanins/immunology , Hemocyanins/therapeutic use , Immunity, Mucosal , Immunoglobulin A/blood , Immunoglobulin M/blood , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Plasmids/administration & dosage , Plasmids/immunology , Plasmids/therapeutic use , Pneumococcal Infections/immunology , Pneumococcal Infections/prevention & control , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunologyABSTRACT
People with multiple sclerosis may present with a wide range of disease symptoms during the evolution of the disease; among these, spasticity can have a marked impact on their well-being and quality of life. Symptom control, including spasticity, remains a key management strategy to improve the patient's well-being and functional status. However, available drug therapies for spasticity sometimes have limited benefit and they are often associated with poor tolerability. Sativex is a 1:1 mix of 9-delta-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with multiple sclerosis is accumulating steadily. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status when Sativex was added to the current treatment regimen. Adverse events such as dizziness, diarrhea, fatigue, nausea, headache and somnolence occur quite frequently with Sativex, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual 'uptitration'. In summary, initial well-controlled studies with Sativex oromucosal spray administered as an add-on to usual therapy have produced promising results and highlight encouraging avenues for future research.
Subject(s)
Multiple Sclerosis/complications , Muscle Spasticity/drug therapy , Parasympatholytics/therapeutic use , Phytotherapy , Plant Extracts/therapeutic use , Administration, Mucosal , Cannabidiol , Dronabinol , Drug Combinations , Humans , Multiple Sclerosis/drug therapy , Multiple Sclerosis/pathology , Muscle Spasticity/etiology , Muscle Spasticity/pathology , Parasympatholytics/administration & dosage , Parasympatholytics/adverse effects , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Randomized Controlled Trials as TopicABSTRACT
In this paper, microdialysis combined with ultra performance liquid chromatography/mass spectrometry (UPLC-MS) was applied for the determination of ligustilide in freely moving rats' brain. The extracellular unbound ligustilide could be detected in rat brain within the first time interval (0-20 min) after nasal administration but not after oral administration. This result showed that ligustilide could quickly enter the brain after nasal administration; which implied that ligustilide may have a rapid onset of action. This work demonstrated the potential application of microdialysis combined with UPLC-MS in pharmacokinetic studies. Furthermore, the advantage that fewer animals used in the microdialysis experiment was confirmed.
Subject(s)
4-Butyrolactone/analogs & derivatives , Brain/metabolism , Ligusticum/chemistry , Plant Extracts/pharmacokinetics , 4-Butyrolactone/administration & dosage , 4-Butyrolactone/pharmacokinetics , Administration, Mucosal , Animals , Chromatography, High Pressure Liquid/methods , Male , Mass Spectrometry/methods , Microdialysis/methods , Nasal Mucosa , Plant Extracts/administration & dosage , Rats , Rats, Sprague-DawleyABSTRACT
Zinc metalloprotease B (ZmpB) is present in all isolated pneumococcal strains and contributes to the pathogenesis of pneumococcal infection. In this study, recombinant ZmpB was cloned and expressed in Escherichia coli. The expression of ZmpB by different pneumococcal strains was detectable by Western blotting with antisera raised to recombinant ZmpB. Flow cytometry analysis demonstrated that anti-ZmpB polyclonal antibodies could bind to the cell surface of the pneumococcal strains analyzed. Both recombinant ZmpB protein and anti-ZmpB polyclonal antibodies significantly inhibited the adhesion of Streptococcus pneumoniae D39 to A549 cells. In mouse models, mucosal immunization with recombinant ZmpB could significantly reduce pneumococcal lung colonization caused by S. pneumoniae serotypes 19F and 14 and significantly increase mice survival times following invasive pneumococcal challenge with different pneumococcal strains, including serotypes 2, 3, 6B, and 14. Furthermore, intraperitoneal immunization with recombinant ZmpB in combination with the recombinant pneumolysin mutant (DeltaA146 Ply) and heat shock protein 40 (DnaJ) could enhance the protection against pneumococcal infection compared to protection provided by single-protein antigens. Passive immunization with hyperimmune antisera against these three antigens also demonstrated that the combination of three hyperimmune antisera could provide better protection than single antisera. Taken together, our results suggest that ZmpB is a good candidate pneumococcal vaccine antigen.